Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Regeneron Pharmaceuticals Stock Performance
NASDAQ:REGN opened at $1,024.09 on Thursday. The stock has a market cap of $112.84 billion, a P/E ratio of 30.25, a price-to-earnings-growth ratio of 2.16 and a beta of 0.13. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The stock’s 50-day moving average is $990.15 and its 200-day moving average is $954.11. Regeneron Pharmaceuticals, Inc. has a 1-year low of $688.52 and a 1-year high of $1,081.17.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.
Wall Street Analyst Weigh In
Read Our Latest Research Report on REGN
Institutional Trading of Regeneron Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the company. West Paces Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $28,000. Fortitude Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $31,000. MCF Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares during the period. Finally, Criterion Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $37,000. 83.31% of the stock is currently owned by institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Using the MarketBeat Dividend Yield Calculator
- AbbVie Stock: A Perfect Dip for Investors to Buy
- What is a Stock Market Index and How Do You Use Them?
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- 3 Warren Buffett Stocks to Buy Now
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.